Hims & Hers stock rises on FDA signals of relaxed peptide restrictions
Hims & Hers (HIMS) stock rose 6% on Thursday as investors reacted positively to signals from Health Secretary Robert F. Kennedy Jr. that the FDA may loosen restrictions on certain peptides. The FDA is set to evaluate these substances in July, which could shift demand away from the black market. However, the stock remains down 23% year-to-date due to ongoing regulatory concerns.
Topics: compounding pharmacies FDA Hims & Hers peptides regulatory risk